Tracon begins phase-1/2 trial of TRC105 antibody therapy for prostate cancer

Tracon begins phase-1/2 trial of TRC105 antibody therapy for prostate cancer
Tracon Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and ophthalmology, announced that the National Cancer Institute has initiated a phase-1/2 clinical trial of TRC105 therapy for patients with castrate-resistant prostate cancer.
Read more on PharmaBiz

SIRA: Prostate Disorders

Join J. Kellogg Parsons, MD, Assistant Professor of Surgery/Urology at UCSD, as he discusses anatomy, function, and disorders of the prostate gland. Two common conditions will be focused on: benign prostatic hyperplasia (swollen prostate) and prostate cancer. Symptoms, diagnosis, and treatment of these disorders will be described. Series: “SIRA (Sam and Rose Stein Institute for [...]

SIRA: Prostate Cancer

National recognized expert, Christopher Kane, MD, Urology Chief, UCSD Medical Center, reviews Prostate Cancer epidemiology and risk assessment information such as serum PSA, clinical stage, Gleason grade and biopsy information. He also reviews the stage and risk migration that has occurred throughout the PSA era. Finally, Dr. Kane reviewed robotic radical prostatectomy and how this [...]

Prostate Cancer Prevention and Screening

Are there modifiable risk factors for prostate cancer? Nutrition? Environment? June Chan, UCSF Division of Cancer Epidemiology, explores the nutritional and hormonal risk factors for prostate cancer. Series: UCSF Mini Medical School for the Public [2/2009] [Health and Medicine] [Show ID: 15574]